Foster City, CA, United States of America

Bruce Fahr

USPTO Granted Patents = 4 


Average Co-Inventor Count = 6.5

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • San Carlos, CA (US) (2006)
  • Foster City, CA (US) (2004 - 2012)

Company Filing History:


Years Active: 2004-2012

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Bruce Fahr: Innovator in Alzheimer's Disease Treatment

Introduction

Bruce Fahr is a notable inventor based in Foster City, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for Alzheimer's disease. With a total of 4 patents, his work focuses on innovative compounds that target critical enzymes involved in neurodegenerative diseases.

Latest Patents

Fahr's latest patents include groundbreaking spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease. The first patent describes spiropiperidine compounds that act as inhibitors of the beta-secretase enzyme, which plays a crucial role in the progression of Alzheimer's disease. This invention also encompasses pharmaceutical compositions that utilize these compounds for effective treatment. The second patent reiterates the utility of spiropiperidine compounds as beta-secretase inhibitors, emphasizing their potential in treating diseases associated with this enzyme. Both patents highlight the importance of these compounds in developing therapeutic strategies for Alzheimer's disease.

Career Highlights

Throughout his career, Bruce Fahr has worked with prominent companies in the pharmaceutical industry. He has been associated with Sunesis Pharmaceuticals, Inc. and Merck Sharp & Dohme Corporation, where he contributed to various innovative projects aimed at improving patient outcomes. His expertise in drug development has positioned him as a key figure in the fight against Alzheimer's disease.

Collaborations

Fahr has collaborated with several professionals in the field, including Craig Alan Coburn and Melissa S. Egbertson. These partnerships have facilitated the advancement of his research and the successful development of his patented compounds.

Conclusion

Bruce Fahr's contributions to the field of Alzheimer's disease treatment through his innovative spiropiperidine compounds demonstrate his commitment to addressing critical health challenges. His work continues to inspire advancements in pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…